Stay updated on Onasemnogene for SMA: Intrathecal Clinical Trial

Sign up to get notified when there's something new on the Onasemnogene for SMA: Intrathecal Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Onasemnogene for SMA: Intrathecal Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The STRONG study (NCT03381729) has been terminated early by the sponsor due to strategic objectives within the intrathecal SMA program. No further enrollment or dosing is planned.
    Difference
    0.4%
    Check dated 2025-11-03T21:04:41.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    32 days ago
    Change Detected
    Summary
    Expanded topic coverage (Spinal muscular atrophy) and updated software version to v3.2.0, replacing the specific term Proximal spinal muscular atrophy and previous v3.1.0.
    Difference
    2%
    Check dated 2025-10-06T05:32:12.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    - Updated version from v3.0.2 to v3.1.0. - No other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T03:05:35.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2 (replacing v3.0.1), indicating a new release. The Back to Top element was removed, which is a minor UI change.
    Difference
    0.1%
    Check dated 2025-09-14T19:18:46.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-07T15:46:13.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has updated its facility name and location details, specifically emphasizing St. Louis, Missouri, and the addition of Zolgensma, a treatment for proximal spinal muscular atrophy.
    Difference
    2%
    Check dated 2025-08-31T11:57:12.000Z thumbnail image

Stay in the know with updates to Onasemnogene for SMA: Intrathecal Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Onasemnogene for SMA: Intrathecal Clinical Trial page.